|
Samir Mitragotri (born May 28, 1971) is an Indian American Professor at the University of California, Santa Barbara, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is the Duncan and Suzanne Mellichamp Chair in Systems Biology and Bioengineering and the Founding Director of the UC Santa Barbara Center for BioEngineering. Mitragotri’s key inventions include technologies that make it possible to deliver medicines into the body without using needles. Many modern medicines including vaccines and insulin are delivered by needles, which cause pain, non-compliance, and infections arising from their misuse. Mitragotri has developed technologies to deliver such medicines through skin patches, topical gels, or oral pills. Most vaccines and medicines cannot enter the body by simply rubbing onto the skin or swallowing because the skin and the gut are designed to serve as a barrier for entry. Mitragotri’s technologies are helping overcome this barrier. He has developed ultrasound devices that can be placed on the skin to increase its porosity, thus allowing for the administration of vaccines (sonophoresis), and needle-free jet devices for the direct administration of medicines (liquid jet injector). He has also designed technologies to optimize topical formulations to safely deliver medicines into the body (INSIGHT) and invented a new class of peptides that can facilitate entry of medicines into skin cells. Collectively, Mitragotri’s inventions are making it possible to deliver medicines into the body in a painless way and offer a better alternative to needle injections for the treatment of various diseases, including diabetes, infectious diseases, and various dermatological conditions. Research in the Mitragotri laboratory is also focused on the engineering of synthetic red blood cells and platelets. These are synthetic particles made from polymers and proteins that mimic key structural properties and certain functional properties of natural blood cells for potential applications in the detection and treatment of cardiovascular diseases. Mitragotri has published over 200 publications in the area of drug delivery and biomaterials, has given over 250 invited presentations worldwide, and is an inventor on about 100 issued or pending patents. His publications are cited with an h-index of 72. Mitragotri is a co-founder of several companies that are developing products based on his inventions for detection and treatment of various human diseases. He received his Ph.D. in Chemical Engineering at MIT and B.S. in Chemical Engineering from the Institute of Chemical Technology. Mitragotri serves on the editorial boards of several journals and currently serves as an Associate Editor of Journal of Controlled Release. ==Awards and Honors== Mitragotri's national and international awards include: * Fellow, (Controlled Release Society ) (CRS) (2015) * Andreas Acrivos Award for Professional Progress, American Institute of Chemical Engineers (AIChE) (2015) * Member, National Academy of Engineering (NAE) (2015) * Fellow, National Academy of Inventors (NAI) (2013) * Fellow, American Association for the Advancement of Science (AAAS) (2012) * Fellow, American Institute for Medical and Biological Engineering (AIMBE) (2010) * (Controlled Release Society )’s Young Scientist Award (2008) * American Institute of Chemical Engineers Allan P. Colburn award (2005) * Selection by MIT's Technology Review Magazine as one of the world’s top Innovators Under 35 (1999) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Samir Mitragotri」の詳細全文を読む スポンサード リンク
|